Pasteurella multocida in Cattle: Bovine Respiratory Disease and Pathogenesis

Introduction

Pasteurella multocida is a Gram-negative, facultatively anaerobic coccobacillus that occupies a central role in the bovine respiratory disease complex (BRDC). BRDC represents a multifactorial syndrome in which viral and bacterial pathogens interact with environmental stressors to produce fibrinous pleuropneumonia, tracheitis, and bronchopneumonia in feedlot cattle and dairy calves. Among the bacterial constituents of BRDC, P. multocida is frequently isolated from pneumonic lungs, often in concert with Mannheimia haemolytica, Histophilus somni, and Mycoplasma bovis. This article provides a detailed clinical reference on Pasteurella multocida bovine respiratory disease, with emphasis on its pathogenesis, diagnostic detection, and control measures in cattle production systems.

Etiology and Taxonomy

Pasteurella multocida belongs to the family Pasteurellaceae, which also includes the genera Mannheimia, Actinobacillus, and Haemophilus. The species is subdivided into five capsular serogroups (A, B, D, E, F) based on capsular polysaccharide antigens and sixteen somatic lipopolysaccharide (LPS) serotypes. In cattle, capsular serogroup A (hyaluronic acid capsule) and, to a lesser extent, serogroup D (heparin-like capsule) are the predominant isolates associated with respiratory disease. Serogroup B and E strains are more commonly linked to hemorrhagic septicemia in cattle and buffalo in tropical regions, a distinct systemic disease separate from BRDC.

The bacterium is a normal commensal of the upper respiratory tract of cattle, residing in the nasopharynx and tonsillar crypts. Disease occurs when host defenses are compromised, allowing translocation to the lower airways. The biotyping scheme based on fermentation of sugars (e.g., sorbitol, dulcitol) aids epidemiological tracking, but molecular typing methods, including pulsed-field gel electrophoresis and multilocus sequence typing, provide higher-resolution discrimination for outbreak investigations.

Epidemiology

Nasal carriage rates of P. multocida in healthy cattle range from 20% to 60%, depending on age, management, and geographic region. Stressors such as weaning, transport, crowding, and inclement weather precipitate shedding and increase the bacterial load in the nasopharynx. Viral infections, particularly with bovine herpesvirus 1 (BHV-1, the agent of infectious bovine rhinotracheitis), bovine respiratory syncytial virus (BRSV), bovine parainfluenza virus 3 (BPIV-3), and bovine coronavirus, impair mucociliary clearance and suppress alveolar macrophage function, creating a permissive environment for P. multocida invasion.

The epidemiology of Pasteurella multocida bovine respiratory disease follows a seasonal pattern, with peak incidence in autumn and winter in temperate zones, corresponding to assembly of feedlot cohorts. Morbidity in affected groups can reach 30% to 50%, with case fatality rates ranging from 5% to 10% in uncomplicated cases and higher when co-infection with M. haemolytica or M. bovis occurs. The disease imposes significant economic losses through mortality, reduced weight gain, treatment costs, and carcass condemnation at slaughter.

Comparison with avian strains of P. multocida is instructive. The same species causes fowl cholera in poultry and waterfowl, with serogroups A and F predominating in birds. The pathophysiology differs markedly: avian infections produce septicemic disease with acute mortality, whereas bovine respiratory disease primarily involves localized pleuropneumonia. For a detailed discussion of P. multocida infections in birds, see the companion articles on Avian Cholera in Waterfowl: Pasteurella multocida Serotypes, Outbreak Dynamics, and Vaccination Approaches in Wild and Domestic Birds and Fowl Cholera in Poultry: Pasteurella multocida Pathogenesis, Clinical Signs, Prevention, Control, and WOAH Classification.

Pathogenesis

The pathogenesis of P. multocida in bovine respiratory disease involves a sequence of adhesion, evasion of phagocytosis, toxin-mediated tissue damage, and host inflammatory response.

Colonization and Invasion

P. multocida adheres to epithelial cells of the upper respiratory tract via filamentous hemagglutinin and autotransporter adhesins. Under normal conditions, the mucociliary escalator and resident alveolar macrophages clear the organism. Viral infection disrupts the ciliated epithelium and induces apoptosis of macrophages, allowing bacteria to proliferate in the lower airways. The bacterium then adheres to type II pneumocytes and bronchiolar epithelial cells.

Capsule and Lipopolysaccharide

The capsular polysaccharide of serogroup A (hyaluronic acid) is a major virulence factor. It inhibits opsonophagocytosis by preventing complement deposition and masking bacterial surface antigens. Hyaluronic acid also mimics host extracellular matrix components, reducing recognition by pattern recognition receptors. The LPS (endotoxin) activates toll-like receptor 4 (TLR4) on alveolar macrophages and epithelial cells, triggering the release of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 (IL-1), and interleukin-8 (IL-8). This cytokine cascade recruits neutrophils to the lung interstitium and alveoli.

Outer Membrane Proteins and Iron Acquisition

Outer membrane proteins (OMPs) such as OmpH and OmpA mediate adherence and biofilm formation. Iron acquisition systems, including transferrin-binding proteins (TbpA/TbpB) and siderophores, enable P. multocida to scavenge iron from host transferrin and hemoglobin, which is essential for growth within the iron-limited pulmonary environment.

Toxins

Strains of P. multocida encoding the toxA gene produce a dermonecrotic toxin (PMT). PMT is a constitutively active intracellular toxin that deamidates the alpha subunit of heterotrimeric G proteins (Gq, Gi, and G12/13), leading to sustained activation of downstream signaling pathways including RhoA, phospholipase C, and mitogen-activated protein kinases. In cattle, PMT contributes to osteolysis in atrophic rhinitis-like lesions and may potentiate pulmonary inflammation, although its role in BRDC is less clearly defined than in porcine respiratory disease. Toxigenic strains of serogroup D and some serogroup A isolates have been recovered from bovine pneumonic lungs.

Inflammatory Response and Tissue Damage

Neutrophil infiltration is a hallmark of P. multocida pneumonia. Neutrophils release elastase, reactive oxygen species, and matrix metalloproteinases that degrade lung parenchyma. The accumulation of fibrin and cellular debris in alveoli produces the characteristic cranioventral consolidation of pneumonic pasteurellosis. If the host response fails to contain the infection, bacteria disseminate to the pleural cavity, causing fibrinous pleuritis. Septicemia is uncommon in BRDC but can occur in immunocompromised animals.

The following Mermaid diagram summarizes the key steps in pathogenesis:

flowchart TD
    A[Viral infection of upper respiratory tract], > B[Loss of ciliated epithelium and macrophage dysfunction]
    B, > C[Increased colonization by P. multocida in nasopharynx]
    C, > D[Aspiration of bacteria into lower airways]
    D, > E[Adhesion to bronchiolar and alveolar epithelium via OMPs and adhesins]
    E, > F[Capsular hyaluronic acid prevents phagocytosis]
    E, > G[LPS activates TLR4 on macrophages and epithelial cells]
    G, > H[Release of TNF-alpha, IL-1, IL-8]
    H, > I[Neutrophil recruitment and degranulation]
    F, > I
    I, > J[Fibrinous exudate, alveolar consolidation, pleuritis]
    J, > K[Clinical pneumonia and respiratory distress]

Clinical Signs and Pathology

Clinical Signs

The incubation period for P. multocida pneumonia after stress or viral exposure is 3 to 7 days. Affected cattle present with acute to subacute onset of depression, anorexia, fever (40.0 to 41.5 degrees C), serous to mucopurulent nasal discharge, tachypnea, and a soft, moist cough. On thoracic auscultation, cranioventral lung fields exhibit crackles, wheezes, and bronchial tones. In severe cases, open-mouth breathing, extended head and neck posture, and cyanosis of mucous membranes indicate marked hypoxemia.

Chronic cases may develop into sequestra formation, with persistent cough, ill-thrift, and occasional episodes of dyspnea. Mortality is typically due to respiratory failure or secondary septicemia.

Gross Pathology

Postmortem examination reveals well-demarcated, cranioventral consolidation of the apical, cardiac, and anterior diaphragmatic lung lobes. Consolidated parenchyma is dark red to gray, firm, and sinks in formalin. Fibrinous adhesions between visceral and parietal pleura are common. Cut surfaces exude serosanguineous or purulent fluid. In chronic cases, encapsulated necrotic foci (sequestra) are present within consolidated tissue. The trachea and bronchi contain frothy, blood-tinged exudate.

Histopathology

Microscopic examination shows a suppurative bronchopneumonia with neutrophils filling alveoli, bronchioles, and interlobular septa. Fibrin deposition is prominent, with proteinaceous edema fluid and alveolar necrosis. Gram-negative coccobacilli are visible in clusters within neutrophils and extracellular spaces. Macrophages and lymphocytes appear in peribronchiolar cuffs in subacute lesions. Sequestra display central coagulation necrosis surrounded by a fibrous capsule and a zone of degenerate neutrophils.

Diagnosis

Antemortem diagnosis relies on clinical scoring, thoracic ultrasonography, and laboratory confirmation. Postmortem diagnosis is accomplished by culture, molecular detection, and histopathology.

Sample Collection

Transtracheal aspiration or bronchoalveolar lavage (BAL) yields representative lower airway samples for cytology and culture. Deep nasal swabs are less specific due to commensal carriage. For postmortem samples, aseptically collected lung tissue, pleural fluid, and tracheal exudate are preferred.

Bacteriological Culture

P. multocida grows on blood agar and chocolate agar under aerobic conditions with 5% to 10% carbon dioxide at 35 to 37 degrees C. Colonies are smooth, gray, and 1 to 2 mm in diameter after 18 to 24 hours and produce a characteristic mouse-like odor. The bacteria are non-hemolytic on sheep blood agar, oxidase-positive, catalase-positive, and ferment glucose, sucrose, and sorbitol. Capsular serogrouping can be performed by multiplex PCR targeting the cap loci.

Molecular Diagnostics

Real-time PCR assays targeting the kmg1 (species-specific) and toxA genes provide rapid, sensitive detection directly from clinical specimens without prior culture. PCR panels for BRDC routinely include P. multocida alongside M. haemolytica, H. somni, and M. bovis. Quantitative PCR can estimate bacterial load, which correlates with disease severity. For detailed information on molecular diagnostics applied to cattle, refer to the article on Mycoplasma bovis in Feedlot Cattle: Chronic Pneumonia, Arthritis, and the Challenge of Cultivation versus Molecular Detection.

Serology

Serological antibody detection is of limited diagnostic value for acute disease due to the ubiquity of the organism as a commensal. Paired serology (acute and convalescent) may demonstrate seroconversion for epidemiological studies but is not recommended for individual case diagnosis.

Differential Diagnosis

The primary differentials for acute bovine respiratory disease include:

Treatment

Antimicrobial therapy should be initiated as early as possible based on clinical signs and ideally guided by culture and susceptibility testing. P. multocida is generally susceptible to oxytetracycline, florfenicol, tilmicosin, tulathromycin, gamithromycin, and ceftiofur. However, antimicrobial resistance is increasing globally, particularly to tetracyclines and sulfonamides. Beta-lactamase production has been reported and is often plasmid-mediated.

The table below summarizes commonly used antimicrobial classes and their typical activity:

Supportive therapy includes non-steroidal anti-inflammatory drugs (e.g., flunixin meglumine) for fever and endotoxemia, and fluid therapy for dehydrated animals. Oxygen supplementation is indicated for severely hypoxemic animals if available.

Control and Prevention

Control of Pasteurella multocida bovine respiratory disease hinges on management practices that reduce stress and limit viral co-infections, combined with strategic vaccination.

Management

Key preventive measures include:

• Minimizing commingling of cattle from different sources.
• Ensuring adequate colostrum intake in neonatal calves to transfer maternal antibodies against viral respiratory pathogens.
• Providing proper ventilation in confined housing to reduce ammonia and airborne particulates.
• Implementing metaphylactic antimicrobial protocols at feedlot arrival for high-risk cattle, typically using a long-acting macrolide or ceftiofur. This practice is controversial due to antimicrobial resistance selection and should be used judiciously.

Vaccination

Commercial vaccines for bovine respiratory disease typically contain inactivated P. multocida serogroup A antigens combined with M. haemolytica and viral components (BHV-1, BRSV, BPIV-3). Autogenous vaccines may be formulated using local isolates when herd-specific serogroups are identified. Vaccination of pregnant cows boosts colostral antibody levels, protecting calves during the neonatal period. In feedlot cattle, booster doses at arrival and revaccination 14 to 21 days later are recommended.

The efficacy of P. multocida bacterins is variable, with field protection estimates ranging from 50% to 75% reduction in clinical disease. Subunit vaccines targeting OMPs or recombinant PMT toxoids are under development but not yet commercially standard.

Biosecurity

Quarantine of new arrivals for 21 days, isolation of sick animals, and maintenance of all-in/all-out groups reduce pathogen transmission. Biocontainment measures should also address viral co-infections, as healthy cattle with intact mucociliary clearance rarely develop P. multocida pneumonia.

Conclusion

Pasteurella multocida remains a significant bacterial agent within the bovine respiratory disease complex, particularly in feedlot and dairy calf populations. Its pathogenesis is driven by capsular evasion of phagocytosis, LPS-mediated inflammation, and, in toxigenic strains, PMT-induced signaling dysregulation. Accurate diagnosis requires culture or molecular detection, and treatment should be guided by local susceptibility profiles. Effective control depends on integrated management, vaccination, and minimization of stress and viral triggers. Continued surveillance for antimicrobial resistance and development of improved vaccines are critical to reducing the global burden of P. multocida bovine respiratory disease.

References

1. Biberstein EL, Hirsh DC. Pasteurella. In: Hirsh DC, Zee YC, editors. Veterinary Microbiology. Malden, MA: Blackwell Science; 1999. p. 142-150.
2. Ackermann MR, Brogden KA. Bovine pneumonic pasteurellosis. In: Gyles CL, Prescott JF, Songer JG, Thoen CO, editors. Pathogenesis of Bacterial Infections in Animals. 4th ed. Ames, IA: Wiley-Blackwell; 2010. p. 223-242.
3. Harper M, Boyce JD, Adler B. Pasteurella multocida pathogenesis: 125 years after Pasteur. FEMS Microbiology Letters. 2006;265(1):1-10.
4. Confer AW. Update on bacterial pathogenesis in BRD. Animal Health Research Reviews. 2009;10(2):145-148.
5. Klima CL, Zaheer R, Cook SR, Booker CW, Hendrick S, Alexander TW, McAllister TA. Pathogens of bovine respiratory disease in North American feedlots conferring multidrug resistance via integrative conjugative elements. Journal of Clinical Microbiology. 2014;52(2):438-448.